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Purpose: To report the case of a patient who presented with a vasculitic central retinal vein occlusion
(CRVO), which was the result of an undiagnosed systemic inﬂammatory condition, seronegative rheu-
matoid arthritis (RA).
Observations: The patient presented with reduced vision in the left eye and polyarthralgia. Fundoscopic
examination revealed a central retinal vein occlusion (CRVO) with concurrent evidence of vasculitis.
Work-up for polyarthralgia included comprehensive serologic testing for connective tissue disease,
including Vectra® disease activity (DA) testing. Results of these studies conﬁrmed the diagnosis of
seronegative rheumatoid arthritis (RA). Systemic steroid therapy was initiated with subsequent anatomic
and visual improvement.
Conclusions and importance: We hypothesize that the systemic inﬂammationda hallmark of RAdled to
the development of a vasculitic CRVO and, thus, the retinal manifestations served as the disease marker
that prompted thorough work-up of the patient's disease, even in the face of initial seronegativity. This
case serves as a reminder that, in the setting of CRVO and polyarthralgia, systemic inﬂammatory con-
ditions must be considered as the underlying etiology. Further, this case report highlights our evolving
understanding of the role that serologic markers play in the diagnosis and monitoring of RA.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is estimated to affect 0.8% of the
world's population, making it the most common inﬂammatory
arthritis [1]. It is characterized by a painful, persistent, and often
symmetrical polyarthritis that primarily involves the synovial tis-
sues. Additionally, RA can be categorized and broadly divided into
two categories based on serology: seropositive RA and seronegative
RA. Approximately 40% of seropositive RA patients experience
extra-articular involvement of multiple organ systems, including
the eyes [2]. Less is known about seronegative RA and its extra-
articular features, but generally speaking seronegative RA is felt
to be less aggressive, with fewer joint erosions and better response
to treatment than seropositive RA [3]. The ophthalmic sequelae of
RA vary widely and range from relatively benign ﬁndings, such as
keratoconjunctivitis sicca and episcleritis, to serious vision-
threatening conditions, including anterior scleritis, necrotizingultants, William Beaumont
oyal Oak, MI 48073, USA.
hawa).
Inc. This is an open access article uscleritis, scleromalacia perforans, peripheral ulcerative keratitis
and retinal vasculitis secondary to posterior scleritis [4].1.1. Case report
Personal identifying information was removed from this report
because informed consent to publish such information was not
obtained. Our patient presented, in the sixth decade of life, with
acute painless vision loss in the left eye that had progressed over
two weeks. In addition, the patient had noticed new onset ﬂoaters.
The patient had no past ocular, medical, surgical, or pertinent
family history, was not taking any medications and at presentation
(as well as on subsequent visits) had a normal blood pressure.
Further questioning did reveal that the patient had been experi-
encing progressive joint stiffness of thewrists and hands for several
months; these symptomsweremost prominent in themorning and
seemed to improve as the day progressed. The involved joints were
mildly edematous and tender to the touch at the meta-
carpophalangeal joints of both hands, suggesting the presence of
active synovitis. Despite the progressive nature of this pain, the
patient had not sought medical attention and had not taken anynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Wideﬁeld color fundus photograph shows dilated and tortuous veins with
scattered ﬂame-shaped hemorrhages, cotton-wool spots and perivascular exudation.
Fig. 3. (A) Spectral-domain optical coherence tomography (SD-OCT) at the time of
presentation showed signiﬁcant macular edema and vitreous cell; (B) On day three of
the initial topical steroid therapy, SD-OCT showed marked improvement of the
intraretinal ﬂuid; (C) On day ten, the macular edema recurred despite continued
topical therapy. Intravitreal ranibizumab was administered at this time. (D) At 3.5
months of monthly ranibizumab treatment, the patient's visual acuity improved to 20/
30 and there was a resolution of the macular edema.
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unifying etiology for the combination of polyarthralgia and
decreased vision in the left eye, the patient was speciﬁcally asked
about a history of hypertension, hyperlipidemia, hypercoagulable
states, immunocompromised states and autoimmune disease; all of
which the patient denied.
On ophthalmic examination, the patient's Snellen visual acuity
(BCVA) was 20/20 in the right eye (OD) and count ﬁngers (CF) at 2
feet in the left eye (OS). Intraocular pressures were 15 mm Hg OD
and 16 mm Hg OS. Anterior segment examination was unremark-
able. Importantly, no cell or ﬂare was detected in the anterior
chamber. Dilated fundus exam of the left eye showed vitreous cell,
dilated and tortuous vessels with perivascular exudation, scattered
ﬂame-shaped hemorrhages and signiﬁcant macular edemadall
consistent with the diagnosis of a central retinal vein occlusion
(CRVO) (Fig. 1). In the early phase, wideﬁeld ﬂuorescein angiog-
raphy (FA) demonstrated multiple venous ﬁlling defects with
associated stretches of capillary non-perfusion (Fig. 2A). In the late
phase (Fig. 2B), wideﬁeld ﬂuorescein angiography was positive for
venous staining and showed mild perivenous leakage. Spectral-
domain optical coherence tomography (SD-OCT) detected exten-
sive intraretinal ﬂuid (between the outer nuclear layer and the
ellipsoid zone), scattered intraretinal ﬂuid in the other layers and
mild vitritis (Fig. 3A). Examination of the OD was unremarkable.
The patient was started on frequent diﬂuprednate 0.05% drops in
the OS, and a broad workup for inﬂammation and vaso-occlusive
disease was initiated in conjunction with the Rheumatology
service.Fig. 2. (A) Early phase wideﬁeld ﬂuorescein angiography showed capillary non-perfusion. (B
perivascular leakage.At three days' follow-up, the patient's VA OS had improved to
20/80 in the left eye, and there was marked improvement of the
intraretinal ﬂuid on SD-OCT without any steroid mediated intra-
ocular pressure increase (Fig. 3B). Based on this response, a sub-
Tenon injection of triamcinolone acetonide was used to supple-
ment the topical therapy. Surprisingly, however, the initial work-up
for occlusive vascular disease was largely uninformative: aside
from a homogenously-positive anti-nuclear antibody (ANA; Titer
1:80) and a mildly elevated Erythrocyte Sedimentation Rate (ESR;
29 mm/h). Other antibodies such as rheumatoid factor (RF), anti-) Late phase wideﬁeld ﬂuorescein angiography showed staining of the vessel wall and
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inﬂammatory, hypercoaguable and autoimmune markers were all
negative (see Table 1). Previously performed magnetic resonance
imaging (MRI) of the hands and wrists did show bony erosions at
the metacarpophalangeal (MCP) joints, a diagnostic ﬁnding for
advanced RA; however, the serologic testing for RA was negative.
Although the combination of the patient's symptomatology,
negative RF/anti-ACPA status and imaging studies established the
diagnosis of seronegative rheumatoid. A Vectra® disease activity
(DA) assay (Crescendo Biosciences, South San Francisco, CA) was
ordered by the collaborating rheumatologist to conﬁrm the diag-
nosis of RA and to assess the level of disease activity. The Vectra®
DA assay objectively measures the levels of 12 serologic markers to
stratify an RA patient's disease activity into 3 groups: low, moderate
and high. The test showed a Vectra® DA Score of 52, which is
consistent with a high level of disease activity. Accordingly, the
patient was started on intravenous methylprednisolone sodium
succinate therapy for 3 days and was then transitioned to oral
prednisone. In addition, the rheumatologist started the patient on a
weekly dose of 15 mg methotrexate sodium with supplemental
folic acid.
At ten days' follow-up, the patient's VA OS had improved to 20/
60. There was concurrent improvement of the retinal tortuosity on
clinical examination, however a slight increase in the intraretinal
ﬂuid was noted on SD-OCT (Fig. 3C). Consequently, anti-vascular
endothelial growth factor (VEGF) therapy was initiated.Table 1
Serologic testing for occlusive vascular disease.
Markers of Autoimmune Disease
Anti-Nuclear Antibody (ANA)*
Rheumatoid Factor
Anti-Cyclic Citrullinated Peptide (ACPA)
Anti-Histone Antibody
Scleroderma Antibody (SCL 70)
Sj€ogren SS A Antibody
Sj€ogren SS B Antibody
Anti-Neutrophil Cytoplasmic Antibody (ANCA)
Extractable Nuclear Antigens (ENA)
Ribonucleoprotien (RNP) Antibody
Smith Antibody
Anti-Double Stranded DNA
Human Leukocyte Antigen (HLA)-B27
Markers of Hypercoagulable States
Antithrombin
Antiphospholipid antibody
Activated Partial Thromboplastin Time (aPTT)
International Normalized Ratio (INR)
Anti Cardiolipin Antibody (IgM, IgG, IgA)
Protein C
Protein S
Factor V Leiden
Prothrombin 20210
Markers of Inﬂammation
C reactive Protein (CRP)
Erythrocyte Sedimentation Rate (ESR)*
Complement Factor 3 (C3)
Complement Factor 4 (C4)
Human Leukocyte Antigen B27 (HLA e B27)
Markers of Infection
B. Burgdorferi Ab Screen
Venereal Disease Research Laboratory (VDRL)
Human Immunodeﬁciency Virus (HIV -1 and HIV 2)
QuantiFERON ®- TB test
Serologic testing for occlusive vascular disease was performed to elucidate possible
etiologic factors which may have contributed to our patient's CRVO. Of these
markers Antinuclear Antibody (ANA) tested homogenously positive with a titer of
1:80 and Erythrocyte Sedimentation Rate (ESR) wasmildly elevated at 29mm/h; the
remaining markers were negative. Although Table 1 does not represent an
exhaustive list of markers for occlusive vascular disease, the patient's history and
physical exam ﬁndings helped to direct the appropriate laboratory testing.Ranibizumab was administered, and the macular edema improved.
At 3.5 months the patient's BCVA was 20/30 with marked
improvement of the edema after monthly injections of ranibizu-
mab (Fig. 3D).
2. Discussion
In this case report, we present a patient who suffered a vasculitic
CRVO as a presenting sign of seronegative RA. Based on the
American Rheumatism Association's 1987 Criteria, a positive
rheumatoid factor was a central component of the diagnosis of RA
[5]. In 2010, a new RA classiﬁcation criteria was introduced, which
intended to identify patients with early RA in order to allow the
initiation of disease-modifying anti-rheumatic drugs (DMARDs)
earlier in the disease course [6]. This classiﬁcation requires a more
detailed assessment of joint involvement and an expansion of
biomarkers. This revised rubric opened the door for seronegative
RA as an ofﬁcial diagnosis [7].
Until recently, there was no objective serologic testing capable
of comprehensively assessing disease activity in seronegative RA
patients [8]. Certain newer biomarker assays have sought to ﬁll this
gap. The Vectra® DA test determines the plasma levels of the
following 12 biomarkers: vascular cell adhesionmolecule 1 (VCAM-
1), vascular endothelial growth factor A (VEGF-A), tumor necrosis
factor receptor-type 1 (TNF-R1), matrix metalloproteinase-3
(MMP-3), leptin, serum amyloid A (SAA), epidermal growth factor
(EGF), interleukin 6 (IL-6), matrix metalloproteinase-1 (MMP-1),
human cartilage glycoprotein 39 (YKL-40), resistin, and C-reactive
protein (CRP) [8]. The test then distills the disparate levels of these
biomarkers to a single numeric value that corresponds to disease
activity and the associated risk of joint damage progression [9].
Retinal vasculitis is a well-known complication of systemic in-
ﬂammatory diseases, such as RA [10]. It is felt that cell mediated
inﬂammation, immune complex mediated inﬂammation and
autoantibody mediated inﬂammation all play a role in the devel-
opment of vasculitis in RA [11]. Inﬂammation, in any of these forms,
can induce vascular intimal proliferation. This intimal proliferation
disrupts laminar ﬂow within blood vessels, predisposing them to
thrombus formation which can lead to local ischemia [12]. Further
research suggests a link between the systemic markers of inﬂam-
mation (CRP and ESR), which are elevated in RA and the increased
risk of atherosclerotic plaque formation in RA patients; suggesting
another possible mechanism of thrombus formation and vascular
occlusion [13]. Yet despite this evidence, the precise pathophysi-
ology which underlies the mechanism of retinal vasculitis and RA
remains unclear.
Regardless of the pathophysiology, a vasculitic CRVO is a rare
ocular complication and an unusual presenting sign of RA. In this
case, successfully identifying retinal vasculitis was of paramount
importance in determining the root cause for our patient's CRVO
and polyarthalgia. Retinal vasculitis is deﬁned as vascular leakage
and/or staining of the vessel walls on ﬂuorescein angiography, with
or without the clinical appearance of ﬂuffy white perivascular in-
ﬁltrates and commonly includes the presence of inﬂammatory cells
in the vitreous body or aqueous humor [14]. Based on the above
criteria, our patient certainly met the deﬁnition of retinal vasculitis,
which is a well-known causative agent of CRVO. To the best of our
knowledge, we present here the ﬁrst report of a vasculitic CRVO in a
patient with seronegative RA, which was deﬁnitively diagnosed
with MRI imaging and conﬁrmed with Vectra® DA testing.
Interestingly, our patient's seronegative statusdin combination
with clear radiographic evidence of RA and a high Vectra® DA
scoredsupport the notion that mechanisms of joint damage and
vasculitis which are not related to RF or anti-ACPA are likely
involved. Our patient's speciﬁc testing showed signiﬁcant
Table 2
Summary of Vectra® DA assay.
Disease Activity Markers Result (Units) RA Percentile (Reference Range)
Adhesion Molecules
Vascular Cell Adhesion Molecule 1 (VCAM-1) 0.51 (mg/mL) 32% (0.35e1.1)
Growth Factors
Epidermal Growth Factor (EGF) 230 (pg/mL) 81% (21e380)
Vascular Endothelial Growth Factor A (VEGF-A) 240 (pg/mL) 46% (83e780)
Cytokine-related Proteins
Interleukin 6 (IL-6) 100 (pg/mL) 97% (2.2e100)
Tumor Necrosis Factor Receptor-Type 1 (TNF-R1) 1.4 (ng/mL) 11% (1.1e4.5)
Matrix Metalloproteinases
Matrix Metalloproteinase-1 (MMP-1) 11 (ng/mL) 55% (3.1e39)
Matrix Metalloproteinase-3 (MMP-3) 38 (ng/mL) 68% (9.2e130)
Skeletal-related Proteins
Human Cartilage Glycoprotein 39 (YKL-40) 99 (ng/mL) 59% (26e440)
Hormones
Leptin 4.2 (ng/mL) 21% (1.0e45)
Resistin 5.7 (ng/mL) 21% (3.6e19)
Acute Phase Proteins
Serum Amyloid A (SAA) 2.5 (mg/mL) 33% (0.64e100)
C-Reactive Protein (CRP) 16 (mg/L) 81% (0.24e77)
Composite Vectra® DA Score 52
Table 2 is a comprehensive summary of Vectra DA® Assay. The patient's composite score was 52, which was considered high disease activity. In addition, you
will ﬁnd not only the results for our patient, but also how these results compare to a reference range that was experimentally determined.
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because these biomarkers are known to be proinﬂammatory they
likely reﬂect the presence of active inﬂammation, which may have
promoted the formation of central retinal vein vasculitis, ultimately
resulting in a CRVO. Current research is underway to more clearly
deﬁne the various “serotypes” of RA and the genetic and environ-
mental inﬂuences which contribute to this heterogenous disease
[15].3. Conclusions
We report a patient who was diagnosed with seronegative RA
with vasculitic CRVO as the presenting sign. Although the classic RA
biomarkers were negative, the patient was eventually diagnosed
with seronegative RA using MRI imaging of the hands. This diag-
nosis was supported by Vectra® DA testing, which showed a high
level of disease activity and helped to direct the proper manage-
mentdincluding appropriate therapy for the patient's vision loss.
Newer biomarker assays, such as the Vectra® DA test, should be
considered in patients with retinal vasculitis and arthritis in the
appropriate clinical situations.References
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